Introduction
============

Understanding the role of blood--brain barrier mechanisms in normal brain development and possible deleterious effects should these mechanisms be dysfunctional is important from the clinical perspective of whether or not drugs or toxins, once they cross the placenta, may have access to the vulnerable developing brain. A reason given by regulatory bodies in US and European Union for caution in giving drugs to pregnant women or infants is "immaturity" of the blood--brain barrier[^1^](#fn1){ref-type="fn"}^,^[^2^](#fn2){ref-type="fn"}.

One historical reason for belief in barrier immaturity comes from teleological thinking that fetal brains would not need a barrier, because the fetus is protected by a placenta (Barcroft, [@B19]). The developing brain is necessarily immature compared to that of the adult, but the real question should be about the functional status of the blood--brain barrier mechanisms in embryos, fetuses, and infants, compared to adults.

There is a widespread belief amongst pediatricians, neurologists, neuroscientists, and neurotoxicologists that "the" blood--brain barrier in the embryo, fetus, and newborn is "immature" implying that it is poorly formed, leaky, or even absent. Statements about the immaturity of the blood--brain barrier frequently seem to be made without evidence, or by reference to an earlier review that also lacks any evidence (e.g., Järup, [@B78]; Costa et al., [@B38]; Watson et al., [@B153]). This seems to be particularly common in the neurotoxicology literature and in toxicology reports (see review by Ek et al., [@B55]).

Functional Significance of Early Development of Brain Barriers
==============================================================

Without the diffusion restraint provided by intercellular junctions in brain barrier interfaces it would not be possible to establish efflux or influx mechanisms such as those controlling ionic gradients between blood and cerebrospinal fluid (CSF; Bito and Myers, [@B27]; Bradbury et al., [@B29]; Amtorp and Sørensen, [@B8]; and see Saunders, [@B122] for review). In effect, these junctions convert the transport properties of individual cerebral endothelial and choroid plexus epithelial cells into those of the whole interfaces separating blood from brain. Thus transfer from blood to brain and CSF occurs across these interfaces and is known to be present from early stages of brain development for a wide range of metabolically important molecules: glucose (Dermietzel et al., [@B47]; Vannucci, [@B146]; Vannucci et al., [@B147]; Bauer et al., [@B23]), amino acids (Braun et al., [@B30]; Cornford et al., [@B37]; Pardridge and Mietus, [@B109]; Lefauconnier and Trouvé, [@B92]), and hormones (Hagenbuch, [@B70]). The molecular structure of tight junctions of the blood--brain barrier proper in the adult brain has been extensively studied and reviewed (e.g., Abbott et al., [@B1]).

Figure [1](#F1){ref-type="fig"} illustrates the brain of an E16 rat brain immunostained with antibodies to total plasma protein. There is no evidence for any proteins escaping the vasculature, demonstrating functional effectiveness of the blood--brain barrier even so early in development. At this stage of rat development in the brain there are very few blood vessels and the cortex only becomes well vascularized after birth. In contrast, choroid plexuses are already a significant size (Figure [1](#F1){ref-type="fig"}C) and grow rapidly during the remainder of gestation. It appears that in early stages of brain development the choroid plexuses are the main portals of molecular transfer from blood into brain (Johansson et al., [@B83]; Liddelow et al., [@B94]).

![**Embryonic day E16 rat brain stained for endogenous plasma proteins**. **(A)** Low power coronal section. Immunostaining in CSF, choroid plexus, and ventricular zone, also few blood vessels in cortex. **(B)** Higher power of cortex: immunostaining in mesenchymal tissue outside brain surface and blood vessels (arrows), not in brain parenchyma. **(C)** Choroid plexus: immunostaining in some epithelial cells (arrowheads) and stroma. **(D)** Immunostaining in neuroependymal cells and blood vessels, not in brain parenchyma outside neuroependyma. Open arrows: sites of strap junctions. Images reproduced from Saunders and Habgood ([@B124]). Scale bars: **(A)**, 100 μm; **(B,D)**, 25 μm; **(C)**, 50 μm.](fphar-03-00046-g001){#F1}

Thus far from being incomplete or "leaky," barriers in developing brain are adapted to fetal environments. However, it is important to distinguish functional effectiveness of early tight junctions at the blood--brain barrier from the evidence for their continued molecular and structural organization. This may relate to increased hydrostatic pressure that occurs during fetal development as systemic blood pressure rises in parallel with plasma protein concentration that provides the "colloid" osmotic pressure important for fluid exchange across capillaries.

Early Studies of the Blood--Brain Barrier in the Developing Brain
=================================================================

Dye experiments
---------------

Ehrlich ([@B54]) and Goldmann ([@B66]) showed that parenteral injections of trypan blue and other acidic dyes resulted in staining of almost all tissues except the brain. Biedl and Kraus ([@B26]) and Lewandowsky ([@B93]) found that even the much smaller molecules: bile and sodium ferrocyanide (demonstrated with Prussian blue reaction) only had toxic effects when injected directly into the brain. It was these early experiments that led to the concept of the brain being protected by a mechanism called the blood--brain barrier, a term that appears to have been first used by Lewandowsky ([@B93]). These experiments were soon followed by similar ones using embryos or newborns of various species. Most of the early reports of experiments using trypan blue gave the same result as in adults, i.e., most of the brain was not stained apart from the circumventricular organs (Wislocki, [@B157], guinea pig embryo; Stern and Peyrot, [@B132]; Stern and Rapoport, [@B133]; Stern et al., [@B134], newborn rats, rabbits, and guinea pigs). Stern et al. ([@B134]) stressed the importance of not injecting too much dye. This may explain one of the few early reports of brain staining following dye injection by Penta ([@B110]) because he used multiple and such large injections that most of his experimental animals (newborn rabbits) died from the toxic effects of the dye (see Saunders, [@B122]). Behnsen ([@B25]) is perhaps the most frequently cited paper supposedly showing staining of the brain following dye injections in postnatal mice. However, his paper did not actually show this but instead his results illustrated that the sites of dye entry in the adult animals corresponded precisely to sites of maximal accumulation in the young mice. Rather curiously Behnsen ([@B25]) chose to illustrate his findings with drawings of sagittal sections using adult mouse brain for both adult and postnatal (2--3 week old) animals. Since areas of the brain such as the cerebral cortex are not yet fully developed at 2--3 weeks of age, the distribution of dye at this age would have appeared more widespread than in the adult, without actually being so. In the brain region with the least mature blood vessels (cerebral cortex) there was no dye staining of the brains of the younger mice. A key often overlooked reference in the field is the one in which both rabbit and human fetal material was studied using trypan blue injections (Gröntoft, [@B67]). The study showed clearly that in human fetuses (5--26 cm long) obtained from legal abortions, providing the dye was injected within 10 min following placental separation, the brains remained dye-free indicating that the blood--brain barrier was impermeable to the dye; at later times or in aborted embryos that could not be examined until some time after delivery, the brains stained blue following dye injection. Gröntoft ([@B67]) considered this to be due to an effect of asphyxia on the blood--brain barrier following the death of the fetuses. He confirmed this under controlled experimental conditions in rabbit fetuses in which he was able to study the brains at predetermined times after injection and death of the fetuses.

Sodium ferrocyanide
-------------------

Sodium ferrocyanide is a small molecular weight compound (mol wt 204) about the same size as sucrose (342 Da; molecular radius 5.1 Å). When treated with acid it gives a blue color (Prussian blue reaction). In what was probably the first brain barrier experiment in an embryo, Weed ([@B154]) injected sodium ferrocyanide into the neural tube of pig embryos (19 mm, E20; term is 114 days) and showed that the blue staining following treatment with slightly acidic solutions of iron salts (Prussian blue reaction) was confined to the neural tube and did not penetrate out into rest of the embryo. This paper seems to have been overlooked by the blood--brain barrier field, perhaps because it is the converse of a classical barrier experiment in which the marker was injected parenterally (cf. Stern and Peyrot, [@B132]; Stern and Rapoport, [@B133]; Stern et al., [@B134]).

In spite of the above studies clearly showing lack of penetration of small molecular compounds even into an embryonic brain, there are nevertheless numerous reports claiming an absence or immaturity of the blood--brain barrier in the fetus and neonate continue to be published (see Ek et al., [@B55] for review).

There are several well-known fetal-specific mechanisms that are different from the adult that reflect adaptation to a fetal-specific environment (e.g., fetal hemoglobin, Palis et al., [@B108]). Similarly, during development, brain barriers demonstrate some important differences, particularly in transport mechanisms, many of which have only recently begun to be described. These differences probably reflect mechanisms important for brain development rather than deficiencies compared to adult brain. This review will summarize the main brain barrier mechanisms in the adult and during development. In the last part of the review we shall consider evidence that blood--brain barrier mechanisms, while functionally effective in the developing brain, may nonetheless be more susceptible than in the adult to adverse circumstances and that damage to brain barrier mechanisms during development may lead to neurological and neuropsychological dysfunction in later life.

Brain Barriers
==============

The main interfaces across which exchange occurs between the blood and the internal environment of the brain (brain interstitial fluid and CSF) are illustrated in Figure [2](#F2){ref-type="fig"}. There are five main barrier interfaces involved: (i) the blood--brain barrier proper at the level of the endothelium of the cerebral blood vessels; (ii) the arachnoid barrier between the CSF in the subarachnoid space and the dura; (iii) the pia/glia limitans between the CSF and extracellular fluid of the brain, which is much more complex in the embryo; (iv) the CSF--brain barrier, which is only a significant barrier in the embryo, created by separation of the ventricular system from the extracellular fluid of the brain by strap junctions in the neuroependyma; and (v) the blood--CSF barrier at the level of the choroid plexus epithelial cells (Figure [2](#F2){ref-type="fig"}).

![**Brain barrier interfaces**. **(A)** Blood--cerebrospinal fluid (CSF) barrier: tight junctions between choroid plexus epithelial cells. **(B)** Blood--brain barrier: tight junctions between endothelial cells. **(C)** CSF--brain barrier only present in embryos and fetuses: strap junctions between neuroependymal cells. **(D)** CSF--brain interface in adult: gap junctions between ependymal cells, with free diffusion pathway (Arrowheads and broken lines). **(E)** Arachnoid barrier. In adult: tight junctions between cells of the inner layer of the arachnoid membrane and between endothelial cells of pial blood vessels. In embryos: additional membrane specializations at the CSF--pial interface (Møllgård et al., [@B99]). Abbreviations: bv, blood vessel; endo, endothelial cell; epi, epithelial cell; bm, basement membrane; peri, pericyte; astro, astrocyte (astrocytes not yet differentiated in brain when blood vessels first appear; thus they cannot contribute to tight junction formation in early brain development). Black arrowheads: sites of tight junctions; open arrowheads: sites of strap junctions. Redrawn from Saunders et al. ([@B123]).](fphar-03-00046-g002){#F2}

Cellular constituents of barrier interfaces in the developing brain
-------------------------------------------------------------------

The principal morphological basis of these barriers lies in intercellular junctions that provide a diffusional restraint between compartments.

### The neurovascular unit

The term blood--brain barrier has a long history, but it has become increasingly recognized that it does not adequately encompass the wide range of morphological features and functional characteristics that it is now known to involve. For this reason the term "neurovascular unit" (Neuwelt, [@B104]) is being increasingly used. It comprises the endothelial cells, pericytes, microglia, astrocytes, and basement membrane that are characteristic of the cerebral vasculature. The term refers more to the close anatomical and functional association of these different cell types without implying any specific mechanisms.

### Endothelial cells

Two features characterize the cerebral endothelial cells that constitute the blood--brain barrier. These are circumferential tight junctions, which occlude the intercellular space between adjacent endothelial cells and a lack of pinocytotic vesicles in the cytoplasm (Brightman and Reese, [@B31]). There are several reports that there are many more vesicles in the endothelial cells of developing brain vasculature (Donahue and Pappas, [@B48]; Dziegielewska et al., [@B50]) with a decline as development proceeds. In contrast Stewart and Hayakawa ([@B135], [@B136]) reported that vesicles were virtually absent in early cerebral blood vessels. This discrepancy could perhaps be due to differences in fixation or to different classes of blood vessels being examined. Dziegielewska et al. ([@B50]) also reported that following intravenous Alcian blue injection in fetal sheep, the dye (which is electron-dense and binds to plasma albumin) could be seen within numerous vesicles and tubules in the cytoplasm of the endothelial cells; dye was also present in the basement membrane, but not inside tight junctions. However, this aspect of brain barrier development has otherwise been little studied. In contrast the question of whether cerebral interendothelial tight junctions in early brain development are as impermeable to markers such as dyes or horseradish peroxidase has attracted a lot of attention, with conflicting results being reported over many years. Thus some early studies using transmission electron microscopy and/or freeze fracture, showed well-formed tight junctions between cerebral endothelial cells from early in vascularization of the brain (Møllgård and Saunders, [@B102]; Møllgård et al., [@B100]; Bass et al., [@B22]; Bauer et al., [@B24]). Some studies claimed that cerebral endothelial tight junctions in fetal mouse and rat brain showed ultrastructural features such as the proportion of the junction composed of zonulae occludens which increased, while junctional clefts decreased, and expanded junctional clefts virtually disappeared (Stewart and Hayakawa, [@B135], [@B136]). In a freeze fracture study, Kniesel et al. ([@B87]) identified changes in strand pattern during cerebral vascular development, which they suggested correlated with greater permeability and subsequent developmental decline in blood--brain barrier permeability. Stewart and Hayakawa ([@B135]) assessed blood--brain barrier permeability by measuring peroxidase activity in homogenized brain at different ages. However, the choroid plexuses are disproportionately larger in the developing brain (Johansson et al., [@B83]) and transfer proteins across their epithelial cells (see below). It is unclear whether choroid plexus was removed from the brain samples and the possibility that HRP may have entered the brain via the plexuses was not considered. Kniesel et al. ([@B87]) did not include any permeability studies in parallel with their ultrastructural observations, but relied on comparisons with *in vitro* cultures of cerebral endothelial cells to support their conclusion that changes in freeze fracture replicas with age correlated with supposed greater blood--brain barrier permeability in the developing brain.

Later studies (Nitta et al., [@B105]; Ek et al., [@B57]) appear to confirm the earlier findings of well-formed tight junctions in the early stages of vascularization of the brain. The advent of small molecular sized water-soluble probes that can be visualized at the electron microscopical level has shown that these junctions are indeed functionally tight to small molecules (Ek et al., [@B57]). Thus in these more recent light microscopical and ultrastructural studies using amounts of tracer that only increased circulating blood volume and protein concentration to a limited extent (\<10%) the tight junctions of endothelial cells in cerebral blood vessels and in embryos and neonates were found to restrict the passage of low molecular weight molecules (Ek et al., [@B57]; Johansson et al., [@B81]; Daneman et al., [@B42]). In contrast, some earlier studies in the developing brain claimed leakiness of cerebral blood vessels, but used large injection volumes or concentrations of the tracer horseradish peroxidase (e.g., Wakai and Hirokawa, [@B151],[@B152]; Risau et al., [@B114]; Risau and Wolburg, [@B115]; see Saunders, [@B122] for review). The more recent findings of Ek et al. ([@B57]), Johansson et al. ([@B81]), and Daneman et al. ([@B42]) show that the physical basis for the brain barrier mechanism is already present and functionally effective from very early in development.

Immunolocalization of tight junctional proteins, such as claudin 5 and occludin, shows that these are present in brain barrier interfaces soon after blood vessels invade the brain in mammals (Ek et al., [@B57]; Daneman et al., [@B42]) including humans (Virgintino et al., [@B150]). Many of the molecular studies of tight junction proteins have been carried out using *in vitro* preparations, often of cultures of artificial cell lines such as Madin--Darby bovine kidney (MDBK) cells and human intestinal epithelial cells (T84; Furuse et al., [@B63], [@B62]; Itoh et al., [@B76]) mouse embryonic feeder cells (Saitou et al., [@B121]) MDCK cells (Sonoda et al., [@B130]; Colegio et al., [@B36]; Blasig et al., [@B28]). These studies have provided valuable insights into the molecular structure of tight junctions, which could then be followed up in material from normal brain endothelia and epithelia *in vitro* (Hirase et al., [@B74]; Haseloff et al., [@B72]; Cohen-Kashi Malina et al., [@B35]) and *in vivo* (Nitta et al., [@B105]; Furuse and Tsukita, [@B64]; Sadowska et al., [@B120]; Xie et al., [@B159]). However, when used to assess barrier interface permeability *in vitro* this has usually been done indirectly by measuring transepithelial or transendothelial resistance (TEER), which is assumed to equate to a low resistance pathway via tight junctions (Frömter and Diamond, [@B61]). It is not clear how well these *in vitro* systems reflect the situation *in vivo*, but it is becoming increasingly clear that they may not always do so, resulting in a number of misleading conclusions. As pointed out by Armulik et al. ([@B10]), it was considered for some years on the basis of *in vitro* studies that pericytes played an important role in development and maintenance of cerebral interendothelial cell tight junctions; however two studies of transgenic mice with deficient pericytes showed that in these animals an increase in vascular permeability correlated with increased endothelial transcytosis rather than tight junction permeability (Armulik et al., [@B9]; Daneman et al., [@B43]) as is discussed in the next section.

### Pericytes

Daneman et al. ([@B43]) compared mice with null and hypomorphic alleles of Pdgfrb (platelet-derived growth factor receptor-β) which have defects in pericyte generation. They showed that pericytes are necessary for formation of a functionally effective blood--brain barrier and that pericyte coverage of blood vessels determines relative vascular permeability. Pericytes were found to regulate functional formation of tight junctions and vesicle trafficking in CNS endothelial cells, however, they did not induce blood--brain barrier specific gene expression in cerebral endothelial cells; rather they inhibited the expression of molecules that increase vascular permeability and infiltration of immune cells. These effects on blood--brain barrier formation occurred a week before the differentiation of astrocytes, the cells that many have suggested are responsible for induction of tight junctions during blood--brain barrier formation (see next section).

### Astrocytes

In the adult brain astrocytic end feet encircle almost the entire circumference of endothelial cells of cerebral capillaries (Caley and Maxwell, [@B32]; Xu and Ling, [@B160]). They are an important component of the neurovascular unit and are thought to make significant contributions to blood--brain barrier functions (Abbott et al., [@B2]). Their role in the developing brain has been more controversial. When *in vitro* blood--brain barrier models were first being developed it was found that the presence of either cultured astrocytes or conditioned medium from cultured astrocytes produced cells with more complex tight junctions (Tao-Cheng et al., [@B143]) and this was essential for the preparation of cerebral endothelial monolayers with high transendothelial resistance (Dehouck et al., [@B45]; Rubin et al., [@B118]). A study that has been particularly influential in discussion of the possible role of astrocytes in development of blood--brain barrier properties in the immature brain was that of Janzer and Raff ([@B77]). These authors cultured cerebral endothelial cells in the anterior chamber of the eye and reported that only in the presence of astrocytes were blood vessels formed that retained dye within their lumena. They compared astrocyte implants with fibroblast implants and found that the vessels associated with the fibroblast grafts were "leaky" to Evans blue. Janzer and Raff ([@B77]) interpreted their results as evidence that blood vessels with impermeable tight junctions were formed in the presence of astrocytes. However, this was not confirmed by electron microscopy; without ultrastructural evidence a claim of tight junction formation was unwarranted. The study was repeated by Holash et al. ([@B75]) who did include electronmicroscopical observations. They found that astrocytes implanted into the anterior chamber formed grafts that were poorly vascularized and when examined by electron microscopy the iridial blood vessels associated with the astrocyte grafts did not change their ultrastructural characteristics to those of brain capillaries. In addition, grafted fibroblasts formed invasive masses that were well vascularized with fenestrated (non-barrier) blood vessels. Holash et al. ([@B75]) suggested that it was the contrast in dye penetration into these well vascularized fibroblast grafts compared to the poorly vascularized astrocyte grafts that led to the incorrect conclusion of barrier formation in vessels penetrating the astrocyte grafts. However, this study is rarely cited in contrast to the paper of Janzer and Raff ([@B77]), a depressing reflection that even scientists will cite the evidence that supports their preconceived ideas, not to mention the undue influence of some journals in which a particular study is published. A limitation of studies of blood--brain barrier interfaces *in vitro* is that the endothelial cells used were generally from adult brains and would therefore already have their adult properties; however it may be that their role is in maintenance of tight junctions rather than in their initial formation.

What seems to have been overlooked by the proponents of the idea that astrocytes are essential for tight junction formation in the blood vessels of the developing brain is that there are no astrocytes present in the developing brain when it is first vascularized (Caley and Maxwell, [@B32]; Daneman et al., [@B42]). As first shown by Stewart and Wiley ([@B137]) using chick-quail chimeras, tight junction formation in cerebral vessels is induced by some factor in the neural tissue of the developing brain. The vessels are tight to proteins and small molecules from as early as vessels first grow into the neural tissue (Bauer et al., [@B24]; Ek et al., [@B57]). It is not yet clear what the induction factor(s) is/are. However, as indicated above it seems that the pericytes make an important contribution to tight junction formation (Daneman et al., [@B43]). The main period of differentiation of astrocytes and the encirclement of capillaries occur in rodents in the first 3 weeks of postnatal life; this is also the main period of vascularization of the developing brain in rodents (Caley and Maxwell, [@B32]). Thus it is possible that astrocytes contribute to tight junction--induction during this period of intense vascularization.

### Basement membrane

The basement membrane surrounds all cerebral capillaries and is an important component of the neurovascular unit. Bär and Wolff ([@B17]) have given a detailed ultrastructural description of formation of the basement membrane around capillaries from E14 in rat cerebral cortex. The basement membrane is thought to be formed by secretion of constituents by cerebral endothelial cells and by pericytes (Stratman and Davis, [@B142]) embedded in this structure (Figure [1](#F1){ref-type="fig"}B). There is also evidence that astrocytes contribute at later stages in vascularization of the brain (del Zoppo and Milner, [@B46]). The main constituents of the basement membrane are type IV collagen from endothelial cells and type I collagen from pericytes as well as fibronectin, thrombospondin (Canfield et al., [@B33]), and agrin (Barber and Lieth, [@B18]). In the developing brain basement membrane is apparent at least as early as E20 in rat fetuses and becomes denser and wider in the postnatal brain (Donahue and Pappas, [@B48]). In human fetuses it has been identified in cerebral capillaries at least as early as 8 weeks gestation in a detailed immunohistochemical study of the distribution of laminin β1 and laminin β2 chains (Roediger et al., [@B117]).

Wnt/βcatenin pathway in blood--brain barrier development
--------------------------------------------------------

A major contribution to understanding the early stages of blood--brain barrier mechanism development was the publication of three papers implicating the Wnt/βcatenin pathway in some important features of blood--brain barrier function (Liebner et al., [@B98]; Stenman et al., [@B131]; Daneman et al., [@B41]). Wnt is an acronym for wingless (wg) first identified in *Drosophila* and INT-1, first identified in virally induced mammary tumors in mice. They are the two founding member genes of the Wnt signaling pathway. Thus far three major pathways downstream from Wnt have been identified. Of these the Wnt/β-catenin pathway seems to be important for aspects of angiogenesis and blood--brain barrier development. The Wnt/βcatenin pathway is also referred to as the canonical Wnt signaling pathway (canonical: "Of the nature of a general rule or standard formula" Oxford English Dictionary). Signaling via Wnt involves a complex molecular mechanism the end result of which is blocking of intracellular mechanisms that would normally result in ubiquitination and proteasome-dependent degradation (Rudloff et al., [@B119]). Several studies have shown that interference with the Wnt/β-catenin pathway results in reduced vessel numbers, loss of capillary beds, and formation of hemorrhagic vascular malformations; in addition Wnt/β-catenin signaling has also been shown to regulate the expression of the blood--brain barrier-specific glucose transporter glut-1 (Stenman et al., [@B131]; Daneman et al., [@B41]). In a study using different transgenic mice at postnatal ages and primary cultures of mouse brain endothelial cells (the age of the animals from which these were derived was not specified) Liebner et al. ([@B98]) reported that Wnt/β-catenin signaling was important for the regulation of two key tight junction proteins, claudin 3 and claudin 5. In contrast, Daneman et al. ([@B41]) reported no effect of down regulation of the Wnt/β-catenin pathway on regulation of the tight junction proteins, occludin and claudin 5 in E11.5 endothelial-specific β-catenin mutants. It is not clear whether this difference was due to the mutants used or the age at which they were examined. The Wnt/β-catenin pathway was found to be active in many endothelial cells of developing brain from as early as E9.5; expression declined after E15.5 to a lower level that was maintained in the neonatal period, but by adulthood expression was rare (Liebner et al., [@B98]).

There is general agreement that Wnt ligands are present in early neural progenitors of the ventricular zone with some regional specificity (Stenman et al., [@B131]; Daneman et al., [@B41]). Thus vascular Wnt activation temporally correlates with the expression of Wnt7a and Wnt7b in the developing forebrain and in the ventral and intermediate spinal cord; Wnt4 in the dorsal and intermediate spinal cord; and Wnt1, Wnt3, and Wnt3a throughout the dorsal neural tube (Daneman et al., [@B41]).

Meningeal barrier
-----------------

At the blood--brain interface over the outer surface of the brain within the pia-arachnoid, the blood vessels also have tight junctions between the endothelial cells, but their cellular transport properties have been little studied. Other important interfaces are between the CSF and brain interstitium at the inner (ventricular) and outer (subarachnoid) spaces. In the adult, cells lining these interfaces are linked by gap junctions, which do not significantly hinder intercellular passage of molecules. However, in the early stages of brain development the cells lining these interfaces are more heterogeneous and are linked by strap junctions, which occlude the intercellular space except to the smallest molecules; this additional barrier provides a specific internal milieu for the developing brain, in contrast to free exchange between CSF and brain present in the adult (Fossan et al., [@B60]; Saunders, [@B122]; Balslev et al., [@B14]).

Choroid plexuses
----------------

The molecular make-up of tight junctions of the blood--CSF barrier is less well-known (Wolburg et al., [@B158]). A recent study of tight junction protein expression in mouse embryos (E15) and adult choroid plexus (Liddelow et al., [@B97]) has shown that several key junctional genes are expressed at a higher level in embryos than in the adults, whereas for several other genes the reverse is the case (Table [1](#T1){ref-type="table"}). This is consistent with previous findings that the fundamental functional basis of this barrier, namely occlusion of the paracellular diffusion pathway, is well established from the earliest stages of differentiation of the choroid plexuses (Bauer et al., [@B24]; Ek et al., [@B56], [@B57]).

###### 

**Tight junction protein genes enriched in mouse lateral ventricular choroid plexus**.

  Gene symbol         GenBank ID   Fold change
  ------------------- ------------ -------------
  **TRANSMEMBRANE**                
  **(A)**                          
  *Pcdh18*            BC052198     6.9
  *Cdh5*              BC054790     4.3
  *Cmtm3*             AY241870     4.0
  *Cdh2*              AB008811     3.4
  *Jam3*              BC024357     3.2
  *Cldn11*            BC021659     2.0
  **(B)**                          
  *Igsf5*             BC004806     9.6
  *Cldn2*             BC085494     4.3
  *Marveld3*          BC025851     4.2
  *Cldn12*            BC024057     2.1

*List of proteins known to be associated with tight junctions whose genes were up-regulated in either the embryo (A) or the adult (B) expressed as fold change compared to levels in other age. From Table [4](#T4){ref-type="table"} in Liddelow et al. ([@B97])*.

Apparent Increased Permeability of Barriers in Developing Brain {#s1}
===============================================================

Small lipid insoluble molecules
-------------------------------

Studies have been carried out in fetuses and newborn of many species using classical radiolabeled physiological permeability markers, sucrose and inulin. These all showed that the earlier in development experiments were conducted, the higher was the apparent permeability (expressed as brain--plasma and CSF--plasma ratios e.g. Habgood et al., [@B68]). This was interpreted by some as evidence for brain barrier "immaturity" (see Saunders, [@B122], for review of earlier studies). However, extensive ultrastructural studies show that the tight junctions at brain barrier sites are formed very early in development (Møllgård and Saunders, [@B102]; Møllgård et al., [@B101]; Tauc et al., [@B144]; Ek et al., [@B59], [@B56], [@B57]). This discrepancy between well-formed tight junctions and higher apparent permeability in the developing brain has only recently been resolved by the use of small lipid insoluble molecules (mainly dextrans of different molecular size) which can be visualized at the electron microscopical level (Ek et al., [@B59], [@B56], [@B57]). At least in short term experiments, tight junctions in cerebral blood vessels and choroid plexus epithelial cells (plexus blood vessels are fenestrated and allow the movement of molecules between the blood and basement membrane) are impermeable to molecules as small as sucrose even when blood vessels first penetrate the brain (Figure [3](#F3){ref-type="fig"}). The observed drop in the concentration ratios can be explained by the initial rapid increase in ventricular volume (occurring as part of normal brain development), which dilutes the entering permeability markers and a low rate of CSF secretion. Subsequent opening of the inner ventricular system to the subarachnoid space and onset of CSF drainage via arachnoid villi (Jones, [@B84]; Jones and Sellars, [@B86]; Jones and Bucknall, [@B85]) with increasing CSF secretion add to further dilution of markers entering CSF. A similar process affects brain distribution of markers because of the presence of a transient CSF--brain barrier at the level of the neuroependymal cells lining the cerebral ventricles (Fossan et al., [@B60]; Møllgård et al., [@B99]).

![**Light (LM) and electronmicrographs (EM) of early developing brain blood vessels and choroid plexus, illustrating functional effectiveness of tight junctions**. **(A)** (LM) and **(B)** (EM) of newborn opossum injected intraperitoneally (i.p.) with 3 kDa biotin dextran. Reaction product confined to vessel lumen **(A)** not passing through tight junctions \[**(B)**, arrowhead\]. **(C)** Newborn opossum choroid plexus injected i.p. with 3 kDa biotin dextran which does not pass through tight junction (arrowhead). **(D)** E15 rat, tracer injected into lateral ventricle. Choroid plexus tight junctions (arrowhead): no passage of tracer between cells. Images: **(A,B)** from Ek et al. ([@B57]); **(C,D)** from Ek et al. ([@B56]). Scale bars: **(A)**, 25 μm; **(B)**, 200 nm; **(C)**, 100 nm; **(D)**, 300 nm.](fphar-03-00046-g003){#F3}

Protein permeability
--------------------

The protein concentration in fetal CSF is high compared to the adult (Dziegielewska and Saunders, [@B53]; Saunders et al., [@B125]). Some authors have interpreted this as evidence that brain barriers (both blood--CSF and blood--brain barrier) are immature in the embryo (Adinolfi et al., [@B4]; Adinolfi and Haddad, [@B5]; Ramey and Birge, [@B113]; Adinolfi, [@B3]). However, there is good experimental evidence that this high protein concentration is a result of transcellular transfer of plasma proteins across choroid plexus epithelial cells (Dziegielewska et al., [@B51], [@B52]; Habgood et al., [@B69]; Knott et al., [@B88]; Liddelow et al., [@B94], [@B95]) reinforced by the slow turnover of CSF in the developing brain (Bass and Lundborg, [@B21]; Johanson and Woodbury, [@B79]) which would be expected to allow proteins entering the CSF via the choroid plexuses to accumulate to a greater extent than in the adult (Johansson et al., [@B83]). These authors also provide a novel interpretation of the results by pointing out that the content of protein in the CSF should be taken into account rather than concentration. Concentration is a function of amounts and the volume in which the protein is distributed. Changes in the volume of distribution would change the concentration without altering the actual amount (see previous section). A general and approximate calculation comparing the amounts of protein in fetal and adult CSF of several species demonstrated that in adult CSF there is actually more protein than in the fetus in spite of CSF protein concentration being much higher in the younger brain (Johansson et al., [@B83]).

Protein Transport from Blood to CSF Across the Choroid Plexuses
===============================================================

Transcellular transfer of plasma proteins was first described over 30 years ago (Dziegielewska et al., [@B51]). It was apparent from the outset that the transfer exhibited a striking degree of developmentally regulated specificity. In particular it was shown that the level of transport of albumin depended upon the species of albumin and the animal species in which it was studied. It is important to make the distinction between proteins made by the choroid plexus itself, e.g., transthyretin. (Schrieber et al., [@B127]), and those proteins transferred between the blood and the CSF. However, transthyretin is also transferred from blood plasma (Dziegielewska et al., [@B51]). Thus in the original experiments, fetal sheep (E60, term is 150 days) transferred their own albumin and bovine albumin to the same steady state level, whereas human and chicken albumins appeared to be discriminated to the extent that their steady state CSF/plasma concentration ratios were about half that of native albumin. A similar phenomenon has been described for albumins in embryonic and neonatal rats (Habgood et al., [@B69]; Johansson et al., [@B81]) postnatal opossum (Knott et al., [@B88]) and in postnatal mice (unpublished). A common characteristic of these experiments is that later in development the species specificity for different albumins disappears (Dziegielewska et al., [@B51]; Habgood et al., [@B69]; Knott et al., [@B88]) but it could also be experimentally abolished by chemical modification of the protein (Habgood et al., [@B69]; Knott et al., [@B88]).

Recent application of physiological and molecular techniques to the study of specific protein transport in the choroid plexus revealed that the plexus epithelial cells contain a number of receptor-/protein-binding-like molecules that have an affinity for albumin and may be the mechanism by which protein is transferred from blood to CSF (Liddelow et al., [@B96]). Three genes: *Sparc*, Glycophorin A (*Gypa*), and C (*Gypc*), were identified as those whose gene products are candidates to target plasma proteins to choroid plexus cells. Sparc and Gypa were identified by immunocytochemistry in choroid plexus epithelial cells in the embryo, subcellular distribution consistent with transport of albumin from blood to CSF, as is illustrated in Figure [4](#F4){ref-type="fig"}. In adult plexus this pattern of immunostaining was absent. This mechanism has been shown to be more specific for individual plasma proteins early in brain development and responsive to changes in concentrations of proteins in plasma presumably as part of a normal homeostatic mechanism (Liddelow et al., [@B94]). In contrast to the one-way (blood to CSF) transport of proteins across the choroid plexus epithelial cells, inert dextrans are transported in both directions (blood to CSF and CSF to blood) with twice as many cells staining for dextrans when administered intraventricularly than intraperitoneally (Figure [5](#F5){ref-type="fig"}).

![**Proposed transepithelial pathway for albumin through choroid plexus epithelial cells**. **(A)** Whole choroid plexus showing single layer of epithelial cells sitting on thick basement membrane (see also Figure [1](#F1){ref-type="fig"}C). **(B)** Suggested routes of albumin from plasma into CSF across the choroid plexus epithelium. GYPA/C in endothelial cells may deliver albumin to basement membrane (1) from where it can be taken up into plexus epithelium by GYPA/C or SPARC (2). Albumin may then travel along a SPARC-specific pathway through tubulocisternal endoplasmic reticulum \[3, and see **(C)**\] and Golgi (4a), or via a VAMP-mediated pathway in vacuoles, lysosomes, or multivesicular bodies \[4b, and see **(C)**\]. On apical surface of plexus epithelium, GYPA/C may be involved in efflux of protein from the cell into CSF (5). In adult, lack of immunoreactivity in endoplasmic reticulum and Golgi and increased expression of gene products for VAMP molecules, suggest that majority of transport occurs via VAMP-mediated vesicular transport (4b). **(C)** Transmission electron micrograph of ultracryosection from E60 fetal sheep choroid plexus (Balslev et al., [@B15]). Immunolabeled human albumin 6 nm particles and sheep albumin 12 nm gold particles are shown to co-localize within the tubulocisternal endoplasmic reticulum. Abbreviations: CPEC, choroid plexus epithelial cell; CSF, cerebrospinal fluid; GYPA, glycophorin A; GYPC, glycophorin C; MVB, multivesicular body; TER, tubulocisternal endoplasmic reticulum. Scale bar: 0.2 μm in **(C)**. Image from Liddelow et al. ([@B97]).](fphar-03-00046-g004){#F4}

![**Cellular localization of fetuin and inert biotin dextran (3 kDa) in postnatal (P9) *Monodelphis domestica***. Light micrograph showing the localization of bovine fetuin **(A,B)** detected with its antibodies and biotin dextran **(C,D)** detected with ABC (ABC kit, Vector Laboratories), in coronal sections of lateral ventricular choroid plexus. **(A)** Twenty-four hours after intraperitoneal injection of bovine fetuin, specific epithelial cells of the plexus (filled arrows) were found containing the protein. **(B)** Bovine fetuin was injected into the lateral ventricle and left for 10 min. The protein was not detected in any cells of the plexus, or in the lumen of blood vessels in the plexus stroma. Protein can be seen on the CSF side of the epithelial cells, precipitated on the brush border (unfilled arrow). **(C)** Forty-five minutes after intraperitoneal injection with BDA (3 kDa), the probe can be seen in specific epithelial cells of the choroid plexus (filled arrow), as well as in the blood vessel lumen (arrowhead) and precipitated in the CSF (unfilled arrow). **(D)** Ten minutes after intraventricular injection with Fluorescein-conjugated BDA (3 kDa), more epithelial cells take up the probe (filled arrows) following CSF injection compared with intraperitoneal injection **(C)**. Penetration of the fluorescent probe between epithelial cells is stopped by the presence of tight junctions (examples highlighted by arrowheads). **(E)** Uptake of bovine fetuin and BDA (3 kDa) into choroid plexus epithelial cells in P9 *Monodelphis* following intraperitoneal or intracerebroventricular injection; mean ± SEM, numbers of immunostained cells. P9 *Monodelphis* injected with fetuin and BDA (3 kDa) intraperitoneally or into one lateral ventricle. \*Percentage of all cells counted. *n* is the number of individual brains used in the study; BDA (3 kDa), biotinylated dextran amine MW 3 kDa. Scale: 50 μm **(A--D)**. From Liddelow et al. ([@B94]) Figure [3](#F3){ref-type="fig"} and Table 7.](fphar-03-00046-g005){#F5}

The proteins transported into CSF across the choroid plexuses have been suggested to have three functions in brain development: (i) some of the proteins are taken up by neural cells present in the ventricular zone that are in contact with the CSF and may have some specific involvement in features of brain development such as mitosis, migration, and differentiation (Stolp et al., [@B141]), (ii) they may act as carriers for growth factors, hormones and vitamins, (iii) the high concentration of proteins in CSF early in brain development may exert a colloid osmotic pressure within the ventricles, thus promoting fluid transfer across the choroid plexuses and contributing to developmental expansion of the ventricles (essential for normal brain growth, see Saunders et al., [@B125]). However, it also needs to be considered that proteins such as albumin are known carriers of heavy metals and drugs, thus in the presence of such toxic molecules this normal mechanism may render the developing brain more vulnerable to such agents (Saunders et al., [@B126]; Ek et al., [@B55]).

Uptake from CSF into Brain
==========================

Once proteins have transferred across the choroid plexus into CSF, some are taken up into cells in the brain. For example some neuroependymal cells lining the cerebral ventricles take up proteins such as albumin and the fetal protein fetuin (Dziegielewska et al., [@B49]). The initial cells that form the first layers of the neocortex in the embryo take up fetuin via apical dendrites that make contact with the dorsal surface of the cortex (Dziegielewska et al., [@B49]). However, this uptake has been little studied and it is not clear whether the proteins themselves are functionally important or bound ligands such as hormones and growth factors. A recent publication indicated that the number of plasma protein positive cells in the ventricular zone of a fetal mouse can be increased following an inflammatory response of the dam indicating that protein uptake into the brain can be physiologically responsive to its changing environment of Stolp et al. ([@B141]).

Influx Mechanisms Across Brain Barriers in the Developing Brain
===============================================================

Amino acid transport
--------------------

Davson ([@B44]) summarized the available evidence on exchange of metabolically important materials between blood and brain in developing animals. On the one hand he accepted Bakay's ([@B11]) results using ^32^P, which showed decreasing uptake with age, as a qualitative indication of the state of the blood--brain barrier. On the other hand he pointed out that greater metabolic incorporation in the developing brain would also contribute to the experimental findings. Bakay ([@B11]) himself discussed both mechanisms and reconciled them by suggesting that his results indicated the presence of a blood--brain barrier in the fetus (rabbit) but that it was more permeable than in the adult. There were similar discussions of the results of experiments studying the entry of amino acids into the developing brain (Himwich et al., [@B73]; Roberts et al., [@B116]; Purpura and Carmichael, [@B112]; Lajtha and Toth, [@B90]; Seta et al., [@B129]; Baños et al., [@B16]) in which the entry of several amino acids was found to be greater in younger animals than in the adult. Kuttner et al. ([@B89]) attempted to get round the difficulty of distinguishing between cerebral endothelial cell transport and metabolic incorporation into brain tissue by studying the uptake of α-aminoisobutyric acid, which is transported but is metabolically inert. They reported a much greater uptake of this amino acid in neonatal rabbits compared to adults but interpreted this as indicating "lesser effectiveness" of the blood--brain barrier for amino acids in young animals; this interpretation was reiterated by others (e.g., Lee, [@B91]). Later studies using the Oldendorf ([@B106]) short pass technique or modifications of the method, allowed separation of entry into the brain from metabolic incorporation. This was done by exposing the cerebral circulation of developing animals to test amino acids and other metabolically active compounds for only a brief period. These experiments showed that many amino acids and other metabolically active compounds were transported into the developing brain at much higher rates than in the adult and was interpreted as reflecting the greater metabolic demand of the developing brain rather than immaturity of the blood--brain barrier (Braun et al., [@B30]; Cornford et al., [@B37]; Pardridge and Mietus, [@B109]; Lefauconnier and Trouvé, [@B92]). However, some authors have continued to suggest that this greater uptake may reflect barrier immaturity (see Watson et al., [@B153]).

It is now clear that the transport mechanisms in the brain barrier interfaces determine the composition of the internal environment of developing brain and supply essential nutrients and other molecules important for growth and differentiation of the brain. Figure [6](#F6){ref-type="fig"} summarizes which inward (blood--brain) transport mechanisms have been shown to be functional in the fetal and newborn brain. Much of the evidence for function of many of these mechanisms was published some time ago and is outlined above (see also reviews by Saunders, [@B122]; Saunders et al., [@B126]; Saunders and Habgood, [@B124]; Liddelow et al., [@B97]).

![**Diagram of main inward transporters in cerebral endothelial cells**. Heavy metals bind to some amino acids and transferrin receptors. Because of vulnerability of developing brain to heavy metals this transport may contribute to fetal or newborn neurotoxicity. Compare Table [2](#T2){ref-type="table"}, which shows transporters expressed in endothelial cells from developing brain, including those up-regulated compared to adult. Abbreviations: ala, alanine; cys, cysteine; Fe^2+^, iron; Glu, glutamate; his, histidine; MCT, monocarboxylate transporter; MeHg, methyl mercury; met, methionine; Mn^2+^, manganese; Pb^2+^, lead; pro, proline; trp, tryptophan; Zn^2+^, zinc.](fphar-03-00046-g006){#F6}

The information that has been lacking until recently is that on the presence and expression level of transporters in the brain barrier interfaces in the developing brain. This is now available from expression studies of isolated cerebral endothelial cells from neonatal mice (Daneman et al., [@B42]) and from choroid plexus of fetal mice compared to the adult (Liddelow et al., [@B97]). Table [2](#T2){ref-type="table"} (from Daneman et al., [@B42]) shows a summary of influx transporters that are up-regulated in the neonatal mouse compared to the adult. Table [3](#T3){ref-type="table"} shows similar data from fetal mouse choroid plexus. It is technically difficult to demonstrate how functionally active these genes are because embryos of common experimental animals are very small. In newborn rats and rabbits several amino acid transporters were shown to be functional at a higher rate than in the adult (Saunders and Habgood, [@B124]). Another example of greater transport in developing brain is inward transport of phosphorylated lysosomal enzymes by the transporter M6P/IGF2R in newborn mice. This transport is progressively lost with age and by adulthood is undetectable (Urayama et al., [@B145]). The findings also help to explain a number of important previous observations on developmentally different effects of amino acids on brain function. For example it was reported many years ago that glutamate is toxic to the brain if administered in the neonatal period (Olney and Ho, [@B107]) which some attributed to "immaturity" of the blood--brain barrier (Viña et al., [@B148]). However, it can now be seen that the barrier contribution to toxicity is much more likely to be due to greater transport by, e.g., Slc1a4, see Table [4](#T4){ref-type="table"}, which summarizes data on expression of influx transporters and published reports on transport function in the developing brain.

###### 

**Expression of transporters in endothelial cells from neonatal mouse brain**.

  Gene ID                                Description
  -------------------------------------- -------------------------------------------
  **BBB ENRICHED INFLUX TRANSPORTERS**   
  **(A)**                                
  Slc1a1                                 Glutamate
  Slc1a4                                 Alanine, serine, cysteine, threonine
  Slc2a1                                 Glucose
  Slc6a6                                 Taurine, β-alanine
  Slc6a17                                AAs, betaine, taurine, creatine
  Slc7a1                                 Cationic AAs
  Slc7a3                                 Cationic AAs
  Slc7a5                                 Neutral AAs
  Slc12a6                                K^+^/Cl^−^
  Slc16a1                                Monocarboxylates
  Slc16a2                                Thyroid hormones
  Slc16a4                                Monocarboxylates
  Slc19a3                                Thiamine
  Slc25a20                               Acylcarnitines
  Slc25a33                               Putative
  Slc30a1                                Zinc
  Slc31a1                                Copper
  Slc35f2                                Putative
  Slc38a3                                Glutamate, Na^+^
  Slc38a5                                Neutral AAs
  Slc39a10                               Zinc
  Slc40a1                                Iron
  Slc46a3                                Putative
  Slco1a4                                Organic anions (e.g., bile acids)
  Slco1c1                                Thyroid hormones
  Slco2b1                                Prostaglandins, organic anions
  **(B)**                                
  Abca5                                  
  Abcb1a                                 Multidrug resistance protein 1
  Abcc4                                  Multidrug resistance associated protein 4
  Abcg2                                  Breast cancer resistance protein

*(A) Influx transporters. Up-regulated glutamate transport probably explains neurotoxic effects of glutamate in immature brain, rather than barrier deficiency (compare Figure [6](#F6){ref-type="fig"}). (B) Efflux transporters (compare Figure [7](#F7){ref-type="fig"}). Data from Daneman et al. ([@B42]). AA, amino acid*.

###### 

**Expression of influx transporters in embryonic mouse choroid plexus**.

  Gene symbol           GenBank ID   Fold change
  --------------------- ------------ -------------
  **SOLUTE CARRIERS**                
  **(A)**                            
  *Slc16a10*            BC052877     66.8
  *Slc6a15*             AY149280     11.4
  *Slc40a1*             AF231120     9.6
  *Slc7a11*             AY766236     7.1
  *Slc4a1*              BC053429     5.5
  *Slc6a13*             BC029637     4.6
  *Slc1a4*              BC043483     4.4
  *Slc38a4*             AY027919     4.2
  *Slc6a6*              L03292       4.1
  *Slc4a4*              AF141934     4.1
  *Slc7a1*              M26687       4.1
  *Slc39a8*             BC006731     3.3
  **(B)**                            
  *Slc5a5*              AF235001     13.6
  *Slc39a4*             BC023498     9.6
  *Slc41a2*             NM_177388    8.5
  *Slc24a4*             AY156046     7.8
  *Slc28a3*             BC013783     6.9
  *Slc24a5*             AB085629     6.1
  *Slc9a7*              BC058750     5.8
  *Slc6a17*             AY155578     3.5
  *Slco1c1*             AY007379     5.2
  *Slc4a10*             AK220501     5.0
  *Slc39a14*            AB177995     4.0
  *Slc35f3*             BC115965     3.9
  *Slc13a4*             BC089161     3.9
  *Slc37a2*             AF121081     3.5
  *Slco1a5*             AF240694     3.4
  *Slc39a12*            BC089362     3.3
  *Slc46a1*             BC057976     3.2
  *Slc25a35*            BC019996     3.1
  *Slc22a5*             AF110417     3.0

*Solute carriers up-regulated in either the embryo (A) or the adult (B). From Table [5](#T5){ref-type="table"} in Liddelow et al. ([@B97])*.

###### 

**Comparison of expression of influx transporters in mouse E15 choroid plexus and published reports on transport function in the developing brain**.

  Transporter   Transport function
  ------------- -------------------------------------------------------
  *Slc16a10*    Iodothyronines T3, T4^1^
  *Slc6a15*     Neutral amino acids^2^
  *Slc40a1*\*   Iron^3^
  *Slc7a11*     Cysteine, glutamate^2^
  *Slc4a1*      Anion transporter^4^, (Cl^−^--HCO~3~ exchange)^5^
  *Slc6a13*     GABA transporter^6^
  *Slc1a4*      Glutamate, neutral amino acids^7^
  *Slc38a4*     Acidic and neutral amino acids^2,7^
  *Slc6a6*      Taurine^2^
  *Slc4a4*      $\text{Na}^{+} - \text{HCO}_{3}^{-}$ cotransporter^4^
  *Slc7a1*      Acidic amino acids^2^
  *Slc39a8*     Zinc transporter^8^

*Only Slc4a4, Slc7a11, and Slc40a1 have previously been identified in choroid plexus. Superscript numbers indicate published studies showing transport into developing brain or CSF. \*Gene product ferroportin-1 identified in choroid plexus. ^1^Porterfield and Hendrich ([@B111]), ^2^Lefauconnier and Trouvé ([@B92]), ^3^Morgan and Moos ([@B103]), ^4^Damkier et al. ([@B39]), ^5^Amtorp and Sørensen ([@B8]), ^6^Al-Sarraf ([@B6]), ^7^Al-Sarraf et al. ([@B7]), ^8^Chowanadisai et al. ([@B34]). From Table 6 in Liddelow et al. ([@B97])*.

Aquaporins
----------

There is also good evidence for appearance of the key water channel aquaporin-1 in very early choroid plexus epithelial cells (Johansson et al., [@B82]). The development of ion gradients between CSF and plasma in the fetal brain suggests that at least some ion pumps are active across the blood--CSF barrier (see Saunders, [@B122]). Molecular expression studies in embryonic choroid plexus confirm that some ion exchange mechanisms are present early in development (Johansson et al., [@B80]; Liddelow et al., [@B97]) and probably also across the blood--brain barrier early in development (Daneman et al., [@B42]). Little is known of what happens if these mechanisms become dysfunctional or develop abnormally.

Efflux Mechanisms Across Brain Barriers in the Developing Brain
===============================================================

An important mechanism in the adult brain at both the blood--brain and blood--CSF barriers are ATP-binding cassette (ABC) efflux transporters (Hartz and Bauer, [@B71]). These transporters are summarized in Figure [7](#F7){ref-type="fig"}. They exclude a large number of toxic but also potentially therapeutic compounds from the brain; thus knowledge of their presence and effectiveness in the developing brain is essential for assessing what risk drugs and toxins may pose. Immunohistochemical studies of P-glycoprotein in human fetuses report its presence in cerebral endothelial cells as early as 8 weeks gestation (Schumacher and Møllgård, [@B128]). Expression and immunohistochemical studies of brain and choroid plexuses in embryonic and adult rats (Ek et al., [@B58]) have shown that known key efflux transporters, multidrug resistance-associated proteins 1 and 4, P-glycoprotein and breast cancer resistance protein (BCRP) are expressed early in both brain and in choroid plexus epithelial cells and that their expression is differentially regulated both with respect to individual efflux transporters and age. It is particularly striking that BCRP is expressed at the highest level in embryonic rat choroid plexus (20-fold compared to adult). In the brain practically no change in expression level for BCRP between the embryo and adult was found (Ek et al., [@B58]). Many of these efflux mechanisms are present and functionally effective in the placenta (see Saunders et al., [@B126]). Data on efflux transporters in embryonic and adult mouse cerebral endothelial cells and choroid plexus are summarized in Tables [3](#T3){ref-type="table"} and [5](#T5){ref-type="table"}. Little is known about the function of efflux transporters in the human newborn brain, but it may be that because of the loss of the protection provided by the placenta, after birth the neonatal brain may be more vulnerable to entry of drugs and toxins.

![**Diagram of main outward transporters in cerebral endothelial cells**. Some, e.g., PGP, (P-glycoprotein) prevent entry. For others, e.g., MRP (multidrug resistance-associated protein), ligand (drug or toxin) combines with glutathione, glucuronic acid or sulfate in cells before efflux.](fphar-03-00046-g007){#F7}

###### 

**Efflux (ABC) transporter expression in embryonic (A) and adult (B) mouse choroid plexus**.

  Gene      Other IDs           Array   qPCR
  --------- ------------------- ------- ------
  **(A)**                               
  *Abcb3*   TAP2                --      16.5
  *Abcb6*   UMAT, MTABC3        2.6     8.1
  *Abcg2*   BCRP                --      15.8
  *Abcg5*   Sterolin1, White3   14.1    44.8
  *Abcg8*   Sterolin2, White4   3.4     20.3
  **(B)**                               
  *Abca2*                       3.5     22.4
  *Abca4*   ABCR, RP19, RIM     9.7     12.9
  *Abca5*                       2.5     1.4
  *Abca7*   ABCX                4.5     --
  *Abcb9*   TAPL                2.8     1.8
  *Abcc1*   MRP, MRP1           2.3     --

*Most enriched genes during development of the mouse lateral ventricular choroid plexus in the embryo or adult. Expression of a further 35 genes was detected at both ages with no difference in expression levels (not shown). Array targets were considered enriched with fold changes equal or greater than 2. From Table 7 in Liddelow et al. ([@B97])*.

Neuropathology of Barrier Mechanisms in the Developing Brain
============================================================

Inflammation
------------

The blood vessels in the developing brain are undoubtedly more fragile than in the adult, which probably explains many of the claims of barrier immaturity or leakiness, stemming from experiments in which excessive volumes of fluid have been injected into fetuses (see Saunders, [@B122] for review). A specific example of susceptibility of cerebral blood vessels in the developing brain is the effect of lipopolysaccharides on permeability of blood vessels in white matter at a critical stage of brain development (Stolp et al., [@B139],[@B140]). These blood vessels show a leakage of plasma proteins, demonstrated in postnatal rats and opossums at a stage of brain development equivalent to 22--28 weeks gestation in humans (Stolp and Dziegielewska, [@B138]). In a clinical context if a mother develops an infection, the fetus may be born prematurely and in some cases white matter damage has been observed with the development of cerebral palsy (Dammann and Leviton, [@B40]; Yoon et al., [@B162]). Leakage of proteins from plasma into white matter in the presence of uterine infection has been suggested to be part of the etiology (Stolp and Dziegielewska, [@B138]). The possible role of barrier dysfunction in the developing brain and subsequent development of neurological/neuropsychiatric disorders such as schizophrenia, Alzheimer's disease and multiple sclerosis has been reviewed (Stolp and Dziegielewska, [@B138]). Most studies seem to have concentrated on changes in permeability to large or small molecules and in properties of tight junctions. The possibility of functionally important changes in influx (Figure [6](#F6){ref-type="fig"}) or efflux (Figure [7](#F7){ref-type="fig"}) mechanisms following a pathological insult to the developing brain scarcely seems to have been considered.

Kernicterus
-----------

Ek et al. ([@B55]) have discussed some possible reasons for the persisting belief amongst for, example neuropathologists and some physiologists and pediatricians that the blood--brain barrier in the developing brain is immature or "leaky." A general reason was given by Barcroft ([@B19]) who expressed the view "There is no reason why the brain of the embryo should require an environment of very great chemical constancy. It will of course require a certain minimum of the various materials necessary for growth, but otherwise on first principles we might suppose that the good things of life may exist in and may vary in the fetal blood to an extent much greater than the maternal." Bakay ([@B12]) expressed a similar view. However, teleological arguments are hardly a rigorous way of determining the mechanism of physiological functions. It seems likely that the proposal that the blood--brain barrier in the fetus and newborn is immature stems in part from a view that prevailed in the middle of the last century that kernicterus (brain damage from excess unconjugated bilirubin in the circulating blood) occurred in prematurely born infants but less commonly in term babies and never in adult, because of immaturity of the blood--brain barrier (e.g., Bakay, [@B11]; Lee, [@B91]). This appears to have been first proposed by Spatz (1934, cited by Davson, [@B44]). Once it became realized that unconjugated bilirubin binds to plasma albumin it was increasingly appreciated that a key determinant of whether or not kernicterus occurred was whether or not this binding capacity was exceeded (e.g., Bakay, [@B13]). However, some have continued to cite claims of immaturity of the blood--brain barrier to small molecules as contributing to kernicterus in newborn infants (Barrett et al., [@B20]). This overlooks the fact that unconjugated bilirubin is lipid soluble and will enter the brain unless bound to plasma albumin. Also greater permeability to small molecules in the immature brain is apparent rather than real as it is due to slow turnover of CSF (see [Apparent Increased Permeability of Barriers in Developing Brain](#s1){ref-type="sec"} above). The commonest cause of kernicterus is erythroblastosis fetalis when excessive amounts of bilirubin are generated from breakdown of incompatible red blood cells in the case of a Rhesus positive baby in a Rhesus negative mother. This tends to be more frequent and more severe in prematurely born infants. However, there seems to be no clear-cut level of unconjugated bilirubin at which all babies will, or will not suffer from kernicterus and it has become increasingly clear that factors in addition to bilirubin binding to albumin are involved (Wennberg, [@B155]; Wennberg et al., [@B156]). Although immaturity of the blood--brain barrier in the sense of "leakiness" is not one of these, there are other brain barrier mechanisms that may contribute. Thus bilirubin is a substrate for the efflux transporter P-glycoprotein and possibly also other efflux transporters (Yokooji et al., [@B161]; Gazzin et al., [@B65]). Although P-glycoprotein is expressed in fetal brain endothelial cells early in gestation its levels are higher in the adult (Schumacher and Møllgård, [@B128]; Virgintino et al., [@B149]; Ek et al., [@B58]) so it is possible that the efflux capacity of P-glycoprotein is exceeded in the presence of high levels of unconjugated bilirubin. Other efflux transporters are present in fetal cerebral endothelial cells and choroid plexus that are expressed at higher levels in the fetus than in the adult (Ek et al., [@B58], see previous section) but it is not clear if bilirubin is also a substrate for these transporters. Another factor is that as described above there is a developmentally regulated transport of albumin from blood to CSF across the epithelial cells of the choroid plexus in the fetal brain. This albumin would presumably carry any bound unconjugated bilirubin into the CSF and thence the brain unless removed by the efflux transporters in the choroid plexuses.

Conclusion
==========

Recent evidence confirms that the brain develops within a well-controlled internal environment. Tight junctions and many of the transport mechanisms (both inward and outward) are already present in the cellular interfaces between the blood, brain, and CSF, very early in development. Some properties of these barrier mechanisms and their susceptibility to disruption may lead to brain damage and later neurological disorders. We hope that this review will contribute to laying to rest the myth of the "leaky" or "immature" blood--brain barrier and focus attention on the need to understand better the level of function of barrier mechanisms that protect the brain from exposure to drugs and toxins, so that clinical advice will be based on the reality of evidence rather than teleological belief.
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